Definitive Upfront Stereotactic Ablative Radiotherapy Combined with Image-Guided, Intensity Modulated Radiotherapy (IG-IMRT) or IG-IMRT Alone for Locally Advanced Non-Small Cell Lung Cancer.

Image-guided (IG) intensity-modulated radiotherapy (IMRT) enables maximal tumor margin reduction for the sparing of organs at risk (OARs) when used to treat locally advanced non-small cell lung cancer (NSCLC) with definitive chemo-radiation. It also allows for the incorporation of stereotactic ablat...

Full description

Bibliographic Details
Main Authors: Alexander Chi, Sijin Wen, Manish Monga, Mohammed Almubarak, Xiaoqing He, Yon Rojanasakul, William Tse, Scot C Remick
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5017732?pdf=render
_version_ 1819274561363902464
author Alexander Chi
Sijin Wen
Manish Monga
Mohammed Almubarak
Xiaoqing He
Yon Rojanasakul
William Tse
Scot C Remick
author_facet Alexander Chi
Sijin Wen
Manish Monga
Mohammed Almubarak
Xiaoqing He
Yon Rojanasakul
William Tse
Scot C Remick
author_sort Alexander Chi
collection DOAJ
description Image-guided (IG) intensity-modulated radiotherapy (IMRT) enables maximal tumor margin reduction for the sparing of organs at risk (OARs) when used to treat locally advanced non-small cell lung cancer (NSCLC) with definitive chemo-radiation. It also allows for the incorporation of stereotactic ablative radiotherapy (SABR) into the treatment regimen. Here, we describe our initial experience in combining definitive upfront SABR to the primary lesion with chemo-radiation delivered with conventionally fractionated IG-IMRT to the remaining regional disease; along with clinical outcome following chemo-radiation with conventionally fractionated IG-IMRT alone in the treatment of locally advanced NSCLC.The clinical outcome of 29 patients with locally advanced NSCLC who underwent conventionally fractionated IG-IMRT, or definitive upfront SABR followed by IG-IMRT combined with chemotherapy (induction, concurrent, or both) was retrospectively reviewed.After a median follow up of 23.7 months, the median overall survival (OS) and progression-free survival (PFS) were 19.8 and 11.3 months, respectively. The 2 year local, regional, and distant control was 60%, 62%, and 38%, respectively. No local failure was observed in 3 patients following SABR + IG-IMRT while 6/26 patients failed locally following IG-IMRT alone. SABR + IG-IMRT was well tolerated. No ≥ grade 3 radiation-related toxicity was observed.Definitive upfront SABR followed by IG-IMRT in selected patients with locally advanced NSCLC warrants further investigation in future clinical trials, while chemo-radiation with IG-IMRT alone was well tolerated.
first_indexed 2024-12-23T23:10:23Z
format Article
id doaj.art-956167ad8c2346d8bf0065365de31576
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-23T23:10:23Z
publishDate 2016-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-956167ad8c2346d8bf0065365de315762022-12-21T17:26:41ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01119e016245310.1371/journal.pone.0162453Definitive Upfront Stereotactic Ablative Radiotherapy Combined with Image-Guided, Intensity Modulated Radiotherapy (IG-IMRT) or IG-IMRT Alone for Locally Advanced Non-Small Cell Lung Cancer.Alexander ChiSijin WenManish MongaMohammed AlmubarakXiaoqing HeYon RojanasakulWilliam TseScot C RemickImage-guided (IG) intensity-modulated radiotherapy (IMRT) enables maximal tumor margin reduction for the sparing of organs at risk (OARs) when used to treat locally advanced non-small cell lung cancer (NSCLC) with definitive chemo-radiation. It also allows for the incorporation of stereotactic ablative radiotherapy (SABR) into the treatment regimen. Here, we describe our initial experience in combining definitive upfront SABR to the primary lesion with chemo-radiation delivered with conventionally fractionated IG-IMRT to the remaining regional disease; along with clinical outcome following chemo-radiation with conventionally fractionated IG-IMRT alone in the treatment of locally advanced NSCLC.The clinical outcome of 29 patients with locally advanced NSCLC who underwent conventionally fractionated IG-IMRT, or definitive upfront SABR followed by IG-IMRT combined with chemotherapy (induction, concurrent, or both) was retrospectively reviewed.After a median follow up of 23.7 months, the median overall survival (OS) and progression-free survival (PFS) were 19.8 and 11.3 months, respectively. The 2 year local, regional, and distant control was 60%, 62%, and 38%, respectively. No local failure was observed in 3 patients following SABR + IG-IMRT while 6/26 patients failed locally following IG-IMRT alone. SABR + IG-IMRT was well tolerated. No ≥ grade 3 radiation-related toxicity was observed.Definitive upfront SABR followed by IG-IMRT in selected patients with locally advanced NSCLC warrants further investigation in future clinical trials, while chemo-radiation with IG-IMRT alone was well tolerated.http://europepmc.org/articles/PMC5017732?pdf=render
spellingShingle Alexander Chi
Sijin Wen
Manish Monga
Mohammed Almubarak
Xiaoqing He
Yon Rojanasakul
William Tse
Scot C Remick
Definitive Upfront Stereotactic Ablative Radiotherapy Combined with Image-Guided, Intensity Modulated Radiotherapy (IG-IMRT) or IG-IMRT Alone for Locally Advanced Non-Small Cell Lung Cancer.
PLoS ONE
title Definitive Upfront Stereotactic Ablative Radiotherapy Combined with Image-Guided, Intensity Modulated Radiotherapy (IG-IMRT) or IG-IMRT Alone for Locally Advanced Non-Small Cell Lung Cancer.
title_full Definitive Upfront Stereotactic Ablative Radiotherapy Combined with Image-Guided, Intensity Modulated Radiotherapy (IG-IMRT) or IG-IMRT Alone for Locally Advanced Non-Small Cell Lung Cancer.
title_fullStr Definitive Upfront Stereotactic Ablative Radiotherapy Combined with Image-Guided, Intensity Modulated Radiotherapy (IG-IMRT) or IG-IMRT Alone for Locally Advanced Non-Small Cell Lung Cancer.
title_full_unstemmed Definitive Upfront Stereotactic Ablative Radiotherapy Combined with Image-Guided, Intensity Modulated Radiotherapy (IG-IMRT) or IG-IMRT Alone for Locally Advanced Non-Small Cell Lung Cancer.
title_short Definitive Upfront Stereotactic Ablative Radiotherapy Combined with Image-Guided, Intensity Modulated Radiotherapy (IG-IMRT) or IG-IMRT Alone for Locally Advanced Non-Small Cell Lung Cancer.
title_sort definitive upfront stereotactic ablative radiotherapy combined with image guided intensity modulated radiotherapy ig imrt or ig imrt alone for locally advanced non small cell lung cancer
url http://europepmc.org/articles/PMC5017732?pdf=render
work_keys_str_mv AT alexanderchi definitiveupfrontstereotacticablativeradiotherapycombinedwithimageguidedintensitymodulatedradiotherapyigimrtorigimrtaloneforlocallyadvancednonsmallcelllungcancer
AT sijinwen definitiveupfrontstereotacticablativeradiotherapycombinedwithimageguidedintensitymodulatedradiotherapyigimrtorigimrtaloneforlocallyadvancednonsmallcelllungcancer
AT manishmonga definitiveupfrontstereotacticablativeradiotherapycombinedwithimageguidedintensitymodulatedradiotherapyigimrtorigimrtaloneforlocallyadvancednonsmallcelllungcancer
AT mohammedalmubarak definitiveupfrontstereotacticablativeradiotherapycombinedwithimageguidedintensitymodulatedradiotherapyigimrtorigimrtaloneforlocallyadvancednonsmallcelllungcancer
AT xiaoqinghe definitiveupfrontstereotacticablativeradiotherapycombinedwithimageguidedintensitymodulatedradiotherapyigimrtorigimrtaloneforlocallyadvancednonsmallcelllungcancer
AT yonrojanasakul definitiveupfrontstereotacticablativeradiotherapycombinedwithimageguidedintensitymodulatedradiotherapyigimrtorigimrtaloneforlocallyadvancednonsmallcelllungcancer
AT williamtse definitiveupfrontstereotacticablativeradiotherapycombinedwithimageguidedintensitymodulatedradiotherapyigimrtorigimrtaloneforlocallyadvancednonsmallcelllungcancer
AT scotcremick definitiveupfrontstereotacticablativeradiotherapycombinedwithimageguidedintensitymodulatedradiotherapyigimrtorigimrtaloneforlocallyadvancednonsmallcelllungcancer